PROPHYLAXIA SIGNS AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO: IG
Ivar Gulla1968
Chairman of the board: BL
Bjørn-Vegard Løvik1978
Years since formation: 14 years; since Jun 9, 2010
Type: Limited company
VAT registered: Yes
Number of employees: 0

Ownership

Number of shares and share classes: 150,000; 1 share class
Total number of shareholders: 3; 2 companies, 1 person

Financials

Total operating income 2023: 2,354,460; NOK
Annual total result 2023: 179,775; NOK
Total equity 2023: -3,688,775; NOK

Last update: Aug 29, 2024

Management

Management / administration

Name	Role	Shares
IG Ivar Gulla 1968	Managing Director/CEO	10.2 % indirectly

Board

Name	Role	Shares
BL Bjørn-Vegard Løvik 1978	Chairman	-
IG Ivar Gulla 1968	Board Member	10.2 % indirectly
PC Patrick Christian Pageat 1960 Resigned	Board Member	-

Others

Name	Role	Shares
P PRAVDA ACCOUNTING AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
IG Ivar Gulla 1968	Managing Director/CEO, Board Member	10.2 % indirectly
JE Johan Emil Andreassen 1977	-	10.01 % indirectly
AI Arne Inge Andreassen 1953	-	1.16 % indirectly

Last update: Apr 13, 2023

Ownership

Company shareholders

Name	Share class	Number of shares	Share
SS Sas Signs	Ordinary shares	73,500	49 %
A ALSCO AQUA AS	Ordinary shares	61,200	40.8 %
A AKVAPROSJEKTER AS	Ordinary shares	15,300	10.2 %

Last update: May 24, 2024

Financials

in NOK

Summary

Year	2023	2022	2021
Total operating income	2,354,460	1,595,940	1,815,613
Annual Total Result	179,775	-1,712,460	-2,040,152
Total assets	5,415,718	2,221,322	5,106,335
Total liabilities	9,104,492	6,089,872	7,262,424
Total equity	-3,688,775	-3,868,549	-2,156,089

P&L

Year	2023	2022	2021
Total operating income	2,354,460	1,595,940	1,815,613
Total operating costs	1,320,748	1,381,817	3,035,923
Operating result	1,033,712	214,123	-1,220,310
Financial income/costs	-853,938	-1,926,583	-819,842
Profit before tax	179,775	-1,712,460	-2,040,152
Total tax & extraordinary income/cost	0	0	0
Annual Total Result	179,775	-1,712,460	-2,040,152

Balance overview

Year	2023	2022	2021
Total fixed assets	0	0	0
Total current assets	5,415,718	2,221,322	5,106,335
Total assets	5,415,718	2,221,322	5,106,335
Short term debt	2,698,359	445,587	344,721
Long term debt	6,406,134	5,644,285	6,917,703
Total liabilities	9,104,492	6,089,872	7,262,424
Contributed capital	8,484,925	8,484,925	8,484,925
Retained earnings	-12,173,700	-12,353,474	-10,641,014
Total equity	-3,688,775	-3,868,549	-2,156,089
Total equity and liabilities	5,415,718	2,221,322	5,106,335

PROPHYLAXIA SIGNS AS995 594 447